Efficacy and safety in triple-versus dual therapy regimens for driver gene-negative nonsquamous non-small cell lung cancer: a systematic review and network meta-analysis
Due to the absence of targetable molecular targets, the treatment of driver gene-negative nonsquamous non-small cell lung cancer (NSCLC) relies primarily on antiangiogenic agents combined with chemotherapy (Antiangio-Ab + Chemo) or immune checkpoint inhibitors combined with chemotherapy regimens (ICI + Chemo). Fu...